Organophosphorus Flame Retardants and Plasticizers in Breast Milk from the United States

Jing Ma,†,‡ Hongkai Zhu,† and Kurunthachalam Kannan*†§

†Wadsworth Center, New York State Department of Health, Albany, New York 12201, United States
‡School of Environmental and Chemical Engineering, Shanghai University, Shanghai 200444, China
§Department of Environmental Health Sciences, School of Public Health, State University of New York at Albany, Albany, New York 12201, United States

Supporting Information

ABSTRACT: Organophosphate esters (OPEs) are used in consumer products as flame retardants and plasticizers. Little is known, however, about the occurrence and profiles of OPEs in human milk. In this study, 14 OPEs were measured in 100 breast milk samples collected from the United States during the period of 2009–2012, using high-performance liquid chromatography and tandem mass spectrometry. The sum concentrations of 14 OPEs in human milk ranged from 0.670 to 7.83 ng/mL, with a mean value of 3.61 ng/mL. The highest mean concentration was found for tris-2-butoxyethyl phosphate (TBOEP, 1.44 ± 0.789 ng/mL), followed by tri-iso-butyl phosphate (TIBP, 0.569 ± 0.272 ng/mL) and tri-n-butyl phosphate (TNPB, 0.539 ± 0.265 ng/mL), which were the dominant OPEs found in breast milk at detection frequencies of >80%. No significant differences were observed between various maternal/infant characteristics and OPE concentrations (p > 0.05), except for TBOEP, for which the median concentrations in Hispanic mothers (0.765 ng/mL) were 2 times lower than those in non-Hispanic mothers (1.48 ng/mL) (p < 0.05). On the basis of the recommended daily milk ingestion rate, the average and the highest daily intakes of total OPEs were calculated to be in the range of 300–542 and 504–911 ng (kg of body weight)−1 day−1, respectively. The estimated daily intakes of OPEs did not exceed the current reference doses. Our study establishes baseline data for OPE exposure in breast-fed American children.

INTRODUCTION

It is challenging to assess the health risks of infant exposure to environmental chemicals present in breast milk, which is a complex and dynamic mixture of endogenous (i.e., fats, water, proteins, carbohydrates, vitamins, and antibodies) and exogenous (i.e., xenobiotics from foods, pharmaceuticals, and the environment) substances delivered to infants through breastfeeding.1,2 Newborns have immature metabolic and immune systems and are prone to exposure to high burdens of exogenous chemicals relative to their body size.3 Breast milk is a major source of exposure to xenobiotics in newborns. For this reason, breast milk has been recognized as one of the important matrices for monitoring organic chemicals, such as polychlorinated biphenyls (PCBs), dioxin/furans, perfluorooalkyl substances (PFASs), polybrominated diphenyl ethers (PBDEs), and bisphenol A (BPA), by the United Nations Environment Program.4–10 Whereas studies have provided evidence of the presence of legacy contaminants in human milk, little is known about the occurrence of organophosphorus flame retardants and plasticizers in human milk from the United States. A few studies from Europe and Asia have reported the presence of organophosphorus flame retardants and plasticizers in breast milk.11–14

Organophosphate esters (OPEs) are widely and increasingly used in consumer products. There are concerns, however, with regard to human exposure to and potential health effects associated with these chemicals. Laboratory animal studies have shown that certain OPEs are neurotoxic, carcinogenic, and reproductive toxicants as well as endocrine disruptors.15–18 Tris(2-ethylhexyl) phosphate (TEHP), tris-2-butoxyethyl phosphate (TBOEP), and tri-n-butyl phosphate (TNPB) were reported to elicit pregnant X receptor agonist activity.19 Triphenyl phosphate (TPHP), TNPB, TBOEP, and tris(2-chloroethyl) phosphate (TCEP) were developmental neurotoxicants.20 Tris-2-chloroisopropyl phosphate (TCIPP) and TCEP were found to affect genes involved in immune responses and steroid hormone biosynthesis and affect xenobiotic metabolic pathways.21 Tris(1,3-dichloroisopropyl)
phosphate (TDCIPP) is listed as a known carcinogen by the Consumer Product Safety Commission. TCEP has been reported to exert adverse effects on key biologic receptors and genes of vertebrate animals. Aryl-OPEs were reported as developmental toxins, and TPHP was reported to disturb homeostasis of sex steroid hormones in human adrenal cells (H295R) and to be associated with increased serum thyroxine levels, especially in women.

Environmental agencies are assessing the risks of OPEs to promulgate regulatory decisions. Nevertheless, production and use of OPEs, which are high-production volume chemicals, have increased sharply worldwide, from 296000 tons in 2004 to 500000 tons in 2011. OPEs are present ubiquitously in various environmental matrices, including water, air, house dust, and foodstuffs. The exposure of humans, especially infants and children, to OPEs is a great concern. Accurate determination of exposure levels and profiles of OPEs in infants is necessary to determine potential health risks.

In this study, 100 human milk samples collected from the United States were analyzed for 14 OPEs. The demographic information was used to determine if they were predictive of or associated with OPE concentrations in human milk. The daily intake of OPEs through the ingestion of breast milk was estimated to assess potential health risks in breast-fed infants.

**MATERIALS AND METHODS**

**Sample Collection.** Breast milk samples were obtained from the archives and sample repository of the Vanguard phase of the U.S. National Children’s Study (NCS). In brief, a total of 100 breast milk samples were collected from the United States in Tennessee (n < 10), Wisconsin (n = 21), South Dakota (n = 29), Maine (n < 10), New York (n = 12), Pennsylvania (n = 17), North Carolina (n < 10), and California (n = 11) between 2009 and 2012. Further details of the samples were reported previously. Mothers were 19–40 years of age (mean of 29.8 years) and in good health, with no documented occupational exposure to OPEs. Demographic information about mothers and children was obtained from the NCS archives and is given in Table S1. The Institutional Review Board of the New York State Department of Health reviewed and approved the analysis of samples. The NCS obtained informed consent from all participants. The samples were selected randomly from the NCS repository, stored in cryogenic vials (Nalgene, Thermo Fisher Scientific, Roskilde, Denmark), and kept on dry ice during transportation to Wadsworth Center. The breast milk samples were stored at −20 °C until further analysis.

**Analytical Methods.** Fourteen triester OPEs were analyzed: trimethyl phosphate (TMP), triethyl phosphate (TEP), tripropyl phosphate (TPP), TNPB, tri-isobutyl phosphate (TIBP), TEHP, TBOEP, TCEP, TCIPP, TPHP, trimethylphenyl phosphate (TMPP), cresyl diphenyl phosphate (CDPP), isodecyl diphenyl phosphate (IDDP), and 2-ethylhexyl diphenyl phosphate (EHDPP). The method for the extraction of OPEs in breast milk samples was similar to that described previously. Briefly, 0.5 mL of breast milk was liquid−liquid extracted with 5 mL of 0.5% formic acid in acetonitrile and then purified by dispersive solid phase extraction (d-SPE) sorbents. Detailed information about the extraction and instrumental analysis by high-performance liquid chromatography and tandem mass spectrometry (HPLC–MS/MS) is provided in Table S2.

**Quality Assurance/Quality Control.** To reduce the background levels of OPEs, all experimental steps were performed in a clean fume hood. Polypropylene (PP) tubes and centrifuge tube filters were precleaned with HPLC-grade n-hexane, methanol, and acetonitrile, in that order, prior to use. MgSO₄ was weighed in clean glass tubes and baked in a muffle furnace at 450 °C for 6 h. Four procedural blanks were analyzed in parallel with every batch of 20 samples to check for background levels of contamination. Twelve compounds, except TPP and TMP, were found in procedural blanks at concentrations that ranged from 0.001 to 0.18 ng/mL. Matrix spikes were prepared by fortifying two different concentrations of target analytes (1 and 5 ng of each) into cow milk purchased from a local supermarket (cow milk was used as a surrogate for breast milk due to its similar composition) and passed through the entire analytical procedure. The matrix spike recoveries ranged from 51% to 112% for individual

---

**Table 1. Distribution of Concentrations of Organophosphate Flame Retardants (nanograms per milliliter) in Breast Milk (n = 100) from the United States**

| OPE          | procedural blank | LOQ | % DF a | (>LOQ) | AM b,c | SD b,c | 25th | 50th | 75th | 95th | range |
|--------------|------------------|-----|--------|--------|--------|--------|------|------|------|------|-------|
| TNBP         | 0.184            | 0.301| 88     | 0.539  | (0.488–0.591)| 0.265 | 0.390 | 0.525 | 0.620 | 1.01 | <LOQ to 1.82 |
| TIBP         | 0.176            | 0.275| 88     | 0.569  | (0.515–0.625)| 0.272 | 0.373 | 0.545 | 0.735 | 1.09 | <LOQ to 1.55 |
| TMPP         | 0.002            | 0.010| 85     | 0.021  | (0.019–0.024)| 0.012 | 0.010 | 0.020 | 0.030 | 0.050 | ND to 0.060 |
| TEP          | 0.154            | 0.354| 32     | 0.350  | (0.287–0.418)| 0.333 | g     | g     | g     | g     | ND to 2.17 |
| TPHP         | 0.032            | 0.109| 55     | 0.149  | (0.119–0.178)| 0.146 | g     | g     | g     | g     | ND to 0.760 |
| TPP          | ND               | 0.023| 0     | ND     | g     | g     | g     | ND    | ND    | ND    | ND |
| TBOEP        | 0.012            | 0.114| 97     | 1.44   | (1.29–1.58)| 0.789 | 0.855 | 1.41  | 1.92  | 2.95  | ND to 4.01 |
| TCEP         | 0.002            | 0.026| 37     | 0.036  | (0.022–0.055)| 0.086 | g     | g     | g     | g     | ND to 0.800 |
| TCIPP        | 0.128            | 0.390| 20     | 0.221  | (0.162–0.289)| 0.326 | g     | g     | g     | g     | ND to 2.51 |
| TEHP         | 0.058            | 0.256| 35     | 0.245  | (0.197–0.291)| 0.244 | g     | g     | g     | g     | ND to 1.23 |
| EHDPP        | 0.002            | 0.010| 25     | 0.022  | (0.016–0.034)| 0.058 | g     | g     | g     | g     | ND to 0.340 |
| IDDP         | 0.005            | 0.023| 19     | 0.013  | (0.011–0.016)| 0.014 | g     | g     | g     | g     | ND to 0.070 |
| CDPP         | 0.001            | 0.005| 12     | 0.005  | (0.002–0.008)| 0.016 | g     | g     | g     | g     | ND to 0.080 |
| TMP          | ND               | 0.166| 0      | ND     | g     | g     | g     | g     | g     | g     | ND |
| ∑OPEs a      | ND               | 1.66 | 0      | 1.40   | 2.64  | 3.46  | 4.47 | 6.07 | 0.670–7.83 |

aLOQ, limit of quantification. bDF, detection frequency. cAM, arithmetic mean (99% confidence intervals). SD, standard deviation. cND, not detected. dValues below LOQ were estimated using LOQ/2 and nondetects were set to zero for statistical analysis. Percentiles are not given because of their low DF (<80%).

DOI: 10.1021/acs.estlett.9b00394

Environmental Science & Technology Letters

Environ. Sci. Technol. Lett. 2019, 6, 525–531
**RESULTS AND DISCUSSION**

**OPE Concentrations and Profiles in Breast Milk.** Mean concentrations and detection frequencies of OPEs in breast milk are summarized in Table 1. Twelve target OPEs, except TPP and TMP, were found in breast milk, with detection frequencies that ranged from 12% to 97%, corroborating the previous findings of the widespread occurrence of OPEs or their metabolites in human urine, breast milk, placenta, plasma, hair, and nails.\(^{12,13,35-37}\) TBOEP, TNBP, TIBP, TMP, and TPHP were quantified in 55–97% of the samples, whereas other compounds were found only in 12–37% of the samples. The highest mean concentration was found for TBOEP (1.44 ± 0.789 ng/mL), followed by TIBP (0.569 ± 0.272 ng/mL), TNBP (0.539 ± 0.265 ng/mL), TEP (0.350 ± 0.333 ng/mL), TEHP (0.245 ± 0.244 ng/mL), TCIPP (0.221 ± 0.326 ng/mL), and TPHP (0.149 ± 0.146 ng/mL), in that decreasing order. The sum concentrations of 12 OPEs (\(\sum\)OPEs) ranged from 0.670 to 7.83 ng/mL, with a mean value of 3.61 ± 1.40 ng/mL, which was comparable to that reported in pooled human milk samples from Sweden (median of 3.37 ng/g, converted from the average lipid content)\(^{11}\) and was >2 times higher than that reported in cow milk (median of 1.55 ng/g) collected from the United States.\(^{27}\) A significant correlation (0.341 < \(r\) < 0.762; \(p < 0.01\)) was found among the concentrations of TNBP, TIBP, TMP, and TBOEP in breast milk samples (Table S4), suggesting a common source for these four compounds.

A wide range of environmental chemicals have been reported to occur in human milk from the United States previously, and the reported mean/median concentrations of each of those chemicals are summarized in Figure 1. The mean concentrations of OPEs (3.61 ng/mL) in breast milk were lower than those of thiocyanate (median of 46.5 ng/mL),\(^{36}\) iodide (median of 45.6 ng/mL),\(^{38}\) PCBs (mean of 5.87 ng/g, converted from the average lipid content),\(^{39}\) perchlorate (median of 4.4 ng/mL),\(^{38}\) and PBDEs (mean of 3.81 ng/g, converted from the average lipid content)\(^{39}\) but were ~2 times higher than the sum concentrations of melamine and its derivatives (mean of 1.72 ng/mL),\(^{9}\) BPA (mean of 2.1 ng/mL),\(^{30}\) and methyl paraben (mean of 1.16 ng/mL).\(^{9}\) Moreover, the mean concentrations of OPEs in breast milk
were 1–2 orders of magnitude higher than those found for arsenic,41 PFASs,4 and hexabromocyclododecanes (HBCDs)42 (mean/median, range of 0.31–0.016 ng/mL). These results further support the significance of OPE exposure in humans.

To the best of our knowledge, OPE concentrations in breast milk were previously reported from Sweden,11 Australia,43 Spain,13 Japan, the Philippines, and Vietnam.12 The same OPE analogues determined in earlier studies with those of ours were TIBP (16%) and TNBP (15%). The composition of OPEs, however, varied widely in breast milk samples from various countries is tempered by the differences in the consumption of TBOEP in the United States was between 454 and 4540 tons in 2012 (Table S5).44 The widespread use of TBOEP in the United States is reflected in its occurrence in freshwater fish from Lake Ontario and herring gull eggs.35–47

### Table 2. Estimated Daily Intakes (EDI; nanograms per kilogram of body weight per day) of Organophosphorus Esters (OPEs) through Breastfeeding in U.S. Infants

| RfD[^a] (ng (kg of bw)^-1 day^-1) | from birth to <1 month (150 ml. (kg of bw)^-1 day^-1) | from 1 to 3 months of age (140 ml. (kg of bw)^-1 day^-1) | from >3 to 6 months of age (110 ml. (kg of bw)^-1 day^-1) | from >6 to 12 months of age (83 ml. (kg of bw)^-1 day^-1) |
|----------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
|                                  | mean | max | mean | max | mean | max | mean | max | mean | max |
| TNBP 2.40 × 10^2                 | 80.9 | 273 | 75.5 | 255 | 59.3 | 200 | 44.7 | 151 |
| TIBP b 85.4 233                   | 79.7 | 217 | 62.6 | 171 | 47.2 | 129 |
| TMPP 1.30 × 10^3                 | 3.15 | 9.00 | 2.94 | 8.40 | 2.31 | 6.60 | 1.74 | 4.98 |
| TEP 1.25 × 10^3                  | 52.5 | 326 | 49.0 | 304 | 38.5 | 239 | 29.1 | 180 |
| TPHP 7.00 × 10^3                 | 22.4 | 114 | 20.9 | 106 | 16.4 | 83.6 | 12.4 | 63.1 |
| TPP b b 0 0                      | 0    | 0   | 0    | 0   | 0    | 0   | 0    | 0   |
| TBOEP 1.50 × 10^3                | 216  | 602 | 202  | 561 | 158  | 441 | 120  | 333 |
| TCEP 2.20 × 10^3                 | 5.40 | 120 | 5.04 | 112 | 3.96 | 88.0 | 2.99 | 66.4 |
| TCIPP 3.60 × 10^3                | 33.1 | 777 | 30.9 | 351 | 24.3 | 276 | 18.3 | 208 |
| TEHP 3.50 × 10^4                 | 36.8 | 185 | 34.3 | 172 | 27.0 | 135 | 20.3 | 102 |
| EHDP 6.00 × 10^5                 | 3.30 | 51.0 | 3.08 | 47.6 | 2.42 | 37.4 | 1.83 | 28.2 |
| IDDP b b 1.95 10.5               | 1.82 | 9.80 | 1.43 | 7.70 | 1.08 | 5.81 | 0.750 | 6.64 |
| CDPP b 0.750 12.0               | 0.700 | 11.2 | 0.550 | 8.80 | 0.420 | 6.64 |
| TMP b 0 0                       | 0    | 0   | 0    | 0   | 0    | 0   |

∑OPEs b 542 911 505 850 397 668 300 504

[^a]: RfD, reference doses from refs 56 and 55. [^b]: Data not available. The average daily breast milk consumption rates (milliliters per day) per infant (kg of bw) were from ref 34.

---

**Demographic Characteristics and OPE Concentrations in Breast Milk.** We examined the differences in the concentrations of four major OPEs, namely, TNBP, TIBP, TMPP, and TBOEP, with various demographic features (Table S6). No significant differences were observed between various maternal/infant characteristics and OPE concentrations (p < 0.05), except for TBOEP, for which the median concentration in Hispanic mothers (0.765 ng/mL) was 2-fold lower than that in non-Hispanic mothers (1.48 ng/mL) (Mann–Whitney U test; p = 0.041). Several studies have reported significant associations between urinary total or individual OPE metabolites and demographic characteristics, such as age, gender, smoking status, and BMI.36,43,48 In addition, studies have shown that body burdens of persistent organic contaminants decrease in women with a history of breastfeeding.49,50

The concentrations of OPEs in breast milk were significantly lower in multiparas than in primiparas in Vietnam, whereas an opposite trend existed for Japanese mothers.51 We did not find significant associations between OPE concentrations in breast milk and maternal characteristics (age or BMI) or temporal factors (season), nor did we find significant differences in OPE concentrations between parity, which may be attributed to the short half-life of OPEs in human bodies and the fact that the concentrations in breast milk reflect daily exposures.52 It is worth noting that small sample sizes analyzed in studies are subject to certain biases.

**Daily Intake of OPEs via Breast Milk.** An infant's daily consumption of breast milk can vary, depending on the infant's age and solid food intake. The U.S. Environmental Protection Agency (EPA) estimated an average daily breast milk consumption rate for infants by age.53 Estimated daily intakes (EDIs) of OPEs were calculated on the basis of the measured concentrations and the consumption rates of breast milk by infants between the ages of 0 and 12 months.

The respective mean and the highest EDIs of ∑OPEs were 542 and 911 ng [kg of body weight (bw)]^-1 day^-1 for infants less than 1 month of age, 505 and 850 ng (kg of bw)^-1 day^-1 for infants between 1 and 3 months of age, and 397 and 668 ng (kg of bw)^-1 day^-1 for infants between 1 and 3 months of age.
for infants from 1 to 3 months of age, 397 and 668 ng (kg of bw)^{-1} day^{-1} for infants from >3 to 6 months of age, and 300 and 504 ng (kg of bw)^{-1} day^{-1} for infants from >6 to 12 months of age, respectively (Table 2). The EDI decreased with an increase in age, which can be explained by increasing body weight and decreasing milk ingestion level with age.

The reference doses (RfD) reported by the U.S. EPA have been used to describe noncarcinogenic risks of environmental toxiancts.53,54 The EDIs were compared with the corresponding RfD values reported for OPEs55,56. The average and highest EDIs of TNBP and TBOEP were 1–2 orders of magnitude lower than the RfDs; the average and highest EDIs of TPHP, TCEP, TCIPP, EHDPP, TEHP, and TMPP were 2–3 orders of magnitude lower than the RfDs. The average and highest hazard quotient (HQ; ratio of EDI to RfD) values of the target OPEs were up to 5 orders of magnitude below 1 (HQ ranged from 7.01 × 10^{-3} to 4.01 × 10^{-1} < 1). These results are similar to those reported previously for six pooled Swedish breast milk samples and 87 Asian breast milk samples.1,12 These results should be interpreted with caution, however, due to the lack of a consensus RfD value for OPEs. Moreover, the concentrations of OPEs are expected to fluctuate in breast milk throughout the feeding period due to the rapid metabolism and elimination of OPEs.1 Nevertheless, breastfeeding has been widely recommended due to a wide range of health benefits for nursing infants, including protection against infection, an improvement in cognitive development, enhancement of the immune system, and provision of balanced and adequate nutrients. Our results establish baseline data on infant exposure to OPEs through breast milk.

This is the first study of the occurrence of OPEs in human milk from the United States. OPE concentrations in the breast milk of U.S. mothers were similar to those reported for PBDEs but 2-fold higher than the concentrations of melamine measured in the same samples. Our OPE concentrations in breast milk were similar to those reported previously for Swedish mothers and were >2-fold higher than those reported in cow milk from the U.S. markets. The composition of OPEs varied widely in breast milk from various countries, in which TBOEP, TNBP, and TIBP were the predominant compounds found in U.S. breast milk. The concentrations of TBOEP in Hispanic mothers were 2-fold lower than those in non-Hispanic mothers in the United States. The EDIs of OPEs through breast milk did not exceed the current RfDs. In addition to triester OPEs, the metabolites of OPEs should be investigated in further studies to assess the risks of OPEs in breast-fed infants.

**ASSOCIATED CONTENT**

* Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.estlett.9b00394.

Demographic characteristics of study participants (Table S1), chemical properties and MS/MS parameters of target OPE compounds (Table S2), information about instrument performance (Table S3), correlation analysis (Table S4), production volumes of OPEs (Table S5), and statistical comparison of select OPE compounds with demographic features (Table S6) and profiles of OPEs in milk samples from different countries (Figure S1) (PDF)

---

### REFERENCES

1. Lehmann, G. M.; LaKind, J. S.; Davis, M. H.; Hines, E. P.; Marchitti, S. A.; Alcala, C.; Lorber, M. Environmental chemicals in breast milk and formula: Exposure and risk assessment implications. *Environ. Health Perspect.* 2018, 126, 096001.
2. Rajewski-Samyt, M.; Sinkiewicz-Darol, E.; Gadzala-Kopciuch, R.; Balsawka-Reyes, M. C.; Gold-Bouchot, G.; Zapata-Perez, O.; Loreto-Gomez, C.; Riosas-Rodriguez, H. Persistent organic pollutants in serum and breast milk of fertile-aged women. *Rev. Int. Contam. Ambiental* 2019, 35, 281–293.
3. Tao, L.; Kannan, K.; Wong, C. M.; Arcauro, K. F.; Butehoff, J. L. Perfluorinated compounds in human milk from Massachusetts, USA. *Environ. Sci. Technol.* 2008, 42, 3096–3101.
4. Weldon, R. H.; Barr, D. B.; Trujillo, C.; Bradman, A.; Holland, N.; Eckernazi, N. A pilot study of pesticides and PCBs in the breast milk of women residing in urban and agricultural communities of California. *J. Environ. Monit.* 2011, 13, 3136–3144.
5. Daniels, J. L.; Pan, I. J.; Jones, R.; Anderson, S.; Patterson, D. G.; Needham, L. L.; Sjodin, A. Individual characteristics associated with PBDE levels in US human milk samples. *Environ. Health Perspect.* 2010, 118, 155–160.
6. LaKind, J. S.; Berlin, C. M.; Sjodin, A.; Turner, W.; Wang, R. Y.; Needham, L. L.; Paul, I. M.; Stokes, J. L.; Naiman, D. Q.; Patterson, D. G. Do Human Milk Concentrations of Persistent Organic Chemicals Really Decline During Lactation? Chemical Concentrations During Lactation and Milk/Serum Partitioning. *Environ. Health Perspect.* 2009, 117, 1625–1631.
7. Zhou, H.; Kannan, K. Occurrence of melamine and its derivatives in breast milk from the United States and its implications for exposure in infants. *Environ. Sci. Technol.* 2019, 53, 7859.
8. Hines, E. P.; Mendola, P.; von Ehrenstein, O. S.; Ye, X. Y.; Calafat, A. M.; Fenton, S. E. Concentrations of environmental phenols and parabens in milk, urine and serum of lactating North Carolina women. *Reprod. Toxicol.* 2015, 54, 120–128.
9. Berglund, M.; Skerfving, S.; Remberger, M.; Calafat, A. M.; Filippin, A. F.; Jansson, B.; Johansson, N.; Appelgren, M.; Hakansson, H. et al. Phthalate diesters and their metabolites in human breast milk, blood or serum, and urine as biomarkers of exposure in vulnerable populations. *Environ. Health Perspect.* 2008, 116, 334–339.
Flame Retardant (FR) Chemicals in Upholstered Furniture Foam.

Chemosphere approaches for the investigation of disrupting effects of tris (2-

Liu, H. L.; Yu, H. X. The combination of in silico and in vivo

organophosphate flame retardants induced cardiotoxicity during

embryogenesis: By disturbing expression of the transcrip-

function.

Environ. Int. 2017, 101, 158–164.

van der Veen, I; de Boer, J. Phosphorus flame retardants: Properties, production, environmental occurrence, toxicity and analysis. Chemosphere 2012, 88, 1119–1153.

Kojima, H.; Takeuchi, S; Itoh, T.; Iida, M.; Kobayashi, S.; Yoshida, T. In vitro endocrine disruption potential of organophosphate flame retardants via human nuclear receptors. Toxicology 2013, 314, 76–83.

Sun, L.; Tan, H.; Peng, T.; Wang, S.; Xu, W.; Qian, H.; Jin, Y.; Fu, Z. Developmental neurotoxicity of organophosphate flame retardants in early life stages of Japanese medaka (Oryzias latipes). Environ. Toxicol. Chem. 2016, 35, 2931–2940.

Krivosheiv, B. V.; Beemster, G. T. S.; Sprangers, K.; Blust, R.; Huuson, S. J. A toxicogenomics approach to screen chlorinated flame retardants tris(2-chloroethyl) phosphate and tris(2-chloroisopropyl) phosphate for potential health effects. J. Appl. Toxicol. 2018, 38, 459–470.

Babich, M. A. CPSC Staff Preliminary Risk Assessment of Flame Retardant (FR) Chemicals in Upholstered Furniture Foam. 2006; pp 1–75. https://www.cpsc.gov/S3s-public/pdfs/ufurn2.pdf.

Wu, Y.; Su, G. Y.; Tang, S.; Liu, W.; Ma, Z. Y.; Zheng, X. M.; Liu, H. L.; Yu, H. X. The combination of in silico and in vivo approaches for the investigation of disrupting effects of tris (2-chloroethyl) phosphate (TCEP) toward core receptors of zebrafish. Chemosphere 2017, 168, 122–130.

Du, Z. K.; Wang, G. W.; Gao, S. X.; Wang, Z. Y. Aryl organophosphate flame retardants induced cardiotoxicity during zebrafish embryogenesis: By disturbing expression of the transcriptional regulators. Aquat. Toxicol. 2015, 161, 25–32.

Rodli, R.; Quintana, J. B.; Reemtsma, T. Liquid chromatog-

raphy-tandem mass spectrometry determination of nonionic organophosphate flame retardants and plasticizers in wastewater samples. Anal. Chem. 2005, 77, 3083–3089.

Chen, Y.; Fang, J. Z.; Ren, L.; Fan, R. F.; Zhang, J. Q.; Liu, G. H.; Zhou, L.; Chen, D. Y.; Yu, Y. X.; Lu, S. Y. Urinary metabolites of organophosphate esters in children in South China: Concentrations, profiles and estimated daily intake. Environ. Pollut. 2018, 235, 358–364.

Wang, Y.; Kannan, K. Concentrations and dietary exposure to organophosphate esters in foodstuffs from Albany, New York, United States. J. Agric. Food Chem. 2018, 66, 13525–13532.

Poma, G.; Sales, C.; Bruyland, B.; Christia, C.; Goscinny, S.; Van Loco, J.; Covaci, A. Occurrence of organophosphate flame retardants and plasticizers (PFRs) in Belgian foodstuffs and estimation of the dietary exposure of the adult population. Environ. Sci. Technol. 2018, 52, 2331–2338.

Poma, G; Glynn, A.; Malarvanan, G.; Covaci, A; Darnerud, P. O. Dietary intake of phosphate flame retardants (PFRs) using Swedish food market basket estimations. Food Chem. Toxicol. 2017, 100, 1–7.

Meeker, J. D.; Stapleton, H. M. House dust concentrations of organophosphate flame retardants in relation to hormone levels and semen quality parameters. Environ. Health Perspect. 2010, 118, 318–323.

Li, X. P.; Xiong, L. L.; Li, D. K.; Chen, C. J.; Cao, Q. Monitoring and exposure assessment of organophosphate flame retardants in source and drinking water, Nanjing, China. Environ. Monit. Assess. 2019, DOI: 10.1007/s10661-019-7239-0.

Cao, Z. G.; Zhao, L. C.; Zhang, Y. C.; Ren, M. H.; Zhang, Y. J.; Liu, X. T.; Jie, J. Y.; Wang, Z. Y.; Li, C. H.; Shen, M. H.; et al. Influence of air pollution on inhalation anddermal exposure of human to organophosphate flame retardants: A case study during a prolonged haze episode. Environ. Sci. Technol. 2019, 53, 3880–3887.

Lehmann, G. M.; Verner, M. A.; Luikinen, B; Henning, C.; Assimon, S. A.; LaKind, J. S.; McLanahan, E. D.; Phillips, L. J.; Davis, M. H.; Powers, C. M.; et al. Improving the risk assessment of lipophilic persistent environmental chemicals in breast milk. Crit. Rev. Toxicol. 2014, 44, 600–617.

Armbruster, D. A.; Pry, T. Limit of blank, limit of detection and limit of quantification. Clin. Biochem. Rev. 2008, 29 (Suppl. 1), S49–S52.

Li, Y. L.; Salamova, A.; He, K.; Hites, R. A. Analysis of polybrominated diphenyl ethers and emerging halogenated and organophosphate flame retardants in human hair and nails. J. Chromatogr. A 2015, 1406, 251–257.

Sun, Y.; Gong, X.; Lin, W.; Liu, Y.; Wang, Y.; Wu, M.; Kannan, K.; Ma, J. Metabolites of organophosphate ester flame retardants in urine from Shanghai, China. Environ. Res. 2018, 164, 507–515.

Ding, J. J.; Xu, Z. M.; Huang, W.; Feng, L. M.; Yang, F. X. Organophosphate ester flame retardants and plasticizers in human placenta in Eastern China. Sci. Total Environ. 2016, 554, 211–217.

Leung, A. M.; Braverman, L. E.; He, X; Schuller, K. E.; Roussilhes, A.; Jahres, K. A.; Pearce, E. N. Environmental perchlorate and thyiocyanate exposures and infant serum thyroid function. Thyroid 2012, 22, 938–943.

She, J.; Holden, A.; Sharp, M.; Tanner, M.; Williams-Derry, C.; Hooper, K. Polybrominated diphenyl ethers (PBDEs) and polychlorinated biphenyls (PCBs) in breast milk from the Pacific Northwest. Chemosphere 2007, 67, 5307–5317.

Mendonca, K.; Hauser, R.; Calafat, A. M.; Arbuckle, T. E.; Duty, S. M. Bisphenol A concentrations in maternal breast milk and infant urine. Int. Arch. Occup. Environ. Health 2014, 87, 13–20.

Carigan, C. C.; Cottingham, K. L.; Jackson, B. P.; Farzan, S. F.; Gandolfi, A. J.; Punshon, T.; Folt, C. L.; Karagas, M. R. Estimated exposure to arsenic in breastfed and formula-fed infants in a United States cohort. Environ. Health Perspect. 2015, 123, 500–506.

Carigan, C. C.; Abdallah, M. A.-E.; Wu, N.; Heiger-Bernays, W.; McClean, M. D.; Harrad, S.; Webster, T. F. Predictors of tetrabromobisphenol-A (TBBP-A) and hexabromocyclododecane (HBCD) milk in from Boston mothers. Environ. Sci. Technol. 2012, 46, 12146–12153.

He, C.; Toms, L. L.; Thai, P.; Van den Eede, N.; Wang, X.; Li, Y.; Baduel, C.; Harden, F. A.; Hefferman, A. L.; Hobson, P.; et al. Urinary metabolites of organophosphate esters: Concentrations and age trends in Australian children. Environ. Int. 2018, 111, 124–130.

U.S. Environmental Protection Agency. Chemical Data Access Tool (CDAT). Chemical Data Reporting (CDR) Results 2016 (data set). https://www.epa.gov/chemical-data-reporting/2016-chemical-data-reporting-results.
(45) Giraudo, M.; Douville, M.; Houde, M. Chronic toxicity evaluation of the flame retardant tris (2-butoxyethyl) phosphate (TBOEP) using Daphnia magna transcriptomic response. Chemosphere 2015, 132, 159–165.

(46) Porter, E.; Crump, D.; Egloff, C.; Chiu, S.; Kennedy, S. W. Use of an avian hepatocyte assay and the avian toxchip polymerase chain reaction array for testing prioritization of 16 organic flame retardants. Environ. Toxicol. Chem. 2014, 33, 573–582.

(47) Chen, D.; Letcher, R. J.; Chu, S. Determination of non-halogenated, chlorinated and brominated organophosphate flame retardants in herring gull eggs based on liquid chromatography-tandem quadrupole mass spectrometry. J. Chromatogr. A 2012, 1220, 169–174.

(48) Lu, S. Y.; Li, Y. X.; Zhang, T.; Cai, D.; Ruan, J. J.; Huang, M. Z.; Wang, L.; Zhang, J. Q.; Qiu, R. L. Effect of e-waste recycling on urinary metabolites of organophosphate flame retardants and plasticizers and their association with oxidative stress. Environ. Sci. Technol. 2017, 51, 2427–2437.

(49) Wang, Y.; Li, W. H.; Martinez-Moral, M. P.; Sun, H. W.; Kannan, K. Metabolites of organophosphate esters in urine from the United States: Concentrations, temporal variability, and exposure assessment. Environ. Int. 2019, 122, 213–221.

(50) Zhang, B.; Lu, S.; Huang, M.; Zhou, M.; Zhou, Z.; Zheng, H.; Jiang, Y.; Bai, X.; Zhang, T. Urinary metabolites of organophosphate flame retardants in 0–5-year-old children: Potential exposure risk for inpatients and home-stay infants. Environ. Pollut. 2018, 243, 318–325.

(51) Wei, B.; Goniewicz, M. L.; O’Connor, R. J.; Travers, M. J.; Harvey, A. J. Urinary metabolite levels of flame retardants in electronic cigarette users: A study using the data from NHANES 2013–2014. Int. J. Environ. Res. Public Health 2018, 15, 201.

(52) He, C.; English, K.; Baduel, C.; Thai, P.; Jagals, P.; Ware, R. S.; Li, Y.; Wang, X.; Sly, P. D.; Mueller, J. F. Concentrations of organophosphate flame retardants and plasticizers in urine from young children in Queensland, Australia and associations with environmental and behavioural factors. Environ. Res. 2018, 164, 262–270.

(53) Hardell, E.; Carlberg, M.; Nordstrom, M.; van Bavel, B. Time trends of persistent organic pollutants in Sweden during 1993–2007 and relation to age, gender, body mass index, breast-feeding and parity. Sci. Total Environ. 2010, 408, 4412–4419.

(54) U.S. Environmental Protection Agency. Exposure factors handbook: 2011 edition (final). 2011. https://cfpub.epa.gov/ncea/cfinfo/recorddisplay.cfm?deid=236252.

(55) U.S. Environmental Protection Agency. Regional screening levels (RSLs)-user’s guide. 2018. https://www.epa.gov/risk/regional-screening-levels-rsls-users-guide.

(56) van den Eede, N.; Dirtu, A. C.; Neels, H.; Covaci, A. Analytical developments and preliminary assessment of human exposure to organophosphate flame retardants from indoor dust. Environ. Int. 2011, 37, 454–461.